Article
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Annals of hematology - 1 Dec 2009
Maloum Karim, Settegrana Catherine, Chapiro Elise, Cazin Bruno, Leprêtre Stéphane, Delmer Alain, Leporrier Michel, Dreyfus Brigitte, Tournilhac Olivier, Mahe Beatrice, Nguyen-Khac Florence, Lesty Claude, Davi Frederic, Merle-Béral Hélène
Abstract excerpt
Several prognostic factors can predict the rapid progression in chronic lymphocytic leukaemia (CLL), including IGHV mutational status, cytogenetic abnormalities and, more recently, LPL/ADAM29 expression. In contrast, few studies have been devoted to the influence of these factors on clinical outcome in responding patients after therapy. We here propose to analyse the impact of IGHV gene status, LPL and ADAM29...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.